Jefferies Lifts PT on Pharmaceuticals Stocks (ABBV) (NVS) (SNY) (PFE)

Jefferies boosted its price targets on a host of pharmaceuticals stocks into Q1 earnings season. The firm is positive on the sector and sees valuation as attractive for most stocks.

The firm's top pick in the US is AbbVie, with Novartis being their most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. Eli Lilly and GlaxoSmithKline are least preferred names.

Price Target Hikes:
AbbVie Inc. (NYSE: ABBV) (Buy) from $45 to $50
Abbott Laboratories (NYSE: ABT) (Buy) from $40 to $42
AstraZeneca PLC (NYSE: AZN) (Hold) from 3,000.00p to 3,100.00p
Bayer AG (Hold) from €79.00 to €84.00
Bristol Myers Squibb (NYSE: BMY) (Buy) FROM $41 to $45
Johnson & Johnson (NYSE: JNJ) (Hold) from $79 to $85
Eli Lilly & Co.(NYSE: LLY) (Underperform) from $43 to $44
Merck & Co., Inc.(NYSE: MRK) (Hold) from $46 to $48
Novartis AG (NYSE: NVS) (Buy) from CHF78.00 to CHF81.00
Pfizer Inc.(NYSE: PFE) (Buy) from $31 to $33
Roche Holding Ltd. (Buy) from CHF230.00 to CHF250.00

Related ETF: The news could have positive implications for sector ETF - SPDR S&P Pharmaceuticals (NYSE: XPH)

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49